Protea Biosciences Group, Inc. 4

4 · Protea Biosciences Group, Inc. · Filed Nov 5, 2014

Form 4

Period: 2014-10-31

Director

Transactions

Conversion
Series A Convertible Preferred Stock
2014-10-31+52,319→ 52,319 total
→ Common Stock (418,552 underlying)
Conversion
Convertible Note
2014-10-31
From: 2014-10-31Exp: 2014-10-31→ Series A Preferred Convertible Stock & Warrants
Conversion
Warrant
2014-10-31+209,276→ 1,502,624 total
Exercise: $0.38From: 2014-10-31Exp: 2017-10-31→ Common Stock (209,276 underlying)

Footnotes (2)

[F1]The Issuer issued Series A Convertible Preferred Stock (the "Preferred Stock") in connection with the conversion of $104,639 outstanding principal and accrued unpaid interest of a certain covertible promissory note (the "Note") to Scott Segal (the "Reporting Person"). Each share of Preferred Stock has a stated value equal to $2.00, subject to increase based on the accrual of a 6% dividend (the "Stated Value"). The Preferred Stock will automatically convert into shares of Common Stock determined by dividing the Stated Value by $0.25 per share on February 17, 2015, subject to extension.
[F2]In connection with th conversion of the Note, the Reporting Person also received a 3 year warrant to purchase up to 209,276 shares of the Company's common stock, exercisable at $0.375 per share.

Documents

1 file